entertainment -WSS

entertainment

author：hotspot 2025-09-30 23:11:05 - browse：6

An ALS patient receives support. -- health coverage from STAT — Adobe

Years of polarizing scientific discourse and bruising online debate will come to a head next week when advisers to the Food and Drug Administration weigh in on NurOwn, a potential treatment to slow the progression of ALS that has bitterly divided physicians and patient advocates.

On Sept. 27, a panel of experts will consider the convoluted data supporting the potential approval of NurOwn, a stem-cell therapy the FDA previously refused to even consider. To some physicians, the drug’s failure to show significant benefits in clinical studies leaves approval out of the question. Others, including the influential ALS Association, say NurOwn’s manufacturer, a small biotech firm called BrainStorm Cell Therapeutics, hasn’t disclosed enough information to properly determine the medicine’s value.

Another group of patients and doctors argue that NurOwn’s supporting evidence, while problematic, justifies making it available to the roughly 30,000 ALS patients in the U.S., people for whom there is currently no hope of arresting an incurable disease that gradually erodes motor function and leads to death within about five years of diagnosis.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Moonlake's readout produced a cash windfall. Risks remain
Next article： Readout Newsletter: Nvidia, Biogen, Ionis, AstraZeneca, ChatGPT

knowledge

WSS

Cancer cells are shown to suck energy source from immune cells

Case highlights the risks of experimental stem cell therapy

Researchers CRISPR chickens in bid to protect them from bird flu

Solving academic medical centers' existential crisis

Wearables generate powerful data but its not useful to doctors, yet

STAT Readout: Today's biotech news includes Sana and Amylyx

Wikipedia

entertainment

focus

Supreme Court strikes down use of affirmative action

NVIDIA and Google execs on the future of AI and drug discovery

The high cost of giving birth even with insurance

European regulators consider appeal over Amylyx ALS drug

The high cost of giving birth even with insurance

Microsoft's Peter Lee says ChatGPT shouldn't be used for initial diagnosis

State Dept. review finds Biden bears some blame for Afghanistan failures

Massive project maps cells in human brain in unprecedented detail

The Supreme Court will review a ruling striking down a domestic violence federal gun ban

The Readout: Lisata, Eisai x Biogen, and the Met Gala (!)

hotspot

How clinical AI models' predictive power can degrade over time

Humana CEO Bruce Broussard to step down in 2024

Humana CEO Bruce Broussard to step down in 2024

Medicare to cover more brain scans related to Alzheimer’s drugs

Bird flu: Don't repeat Covid's 'health versus the economy' framing

Helping hospitals and community health centers plan for resilience

focus

knowledge

entertainment

focus